Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen?

@article{Rabiner2007ImagingOS,
  title={Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen?},
  author={Eugenii A. Rabiner},
  journal={Journal of Psychopharmacology},
  year={2007},
  volume={21},
  pages={253 - 258}
}
  • E. Rabiner
  • Published 2007
  • Psychology, Medicine
  • Journal of Psychopharmacology
Increased release of striatal dopamine, indexed with in vivo imaging of the D2 receptor, has been reported following an acute challenge with N-methyl-D-aspartate (NMDA) antagonist ketamine in humans. Replications of this result have not been consistently successful. The aim of this manuscript is to evaluate in vivo imaging examination of NMDA antagonism on striataL dopamine release in published reports of humans and pre-clinical species. The literature is evaluated in conjunction with insights… Expand
The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders
TLDR
Evidence is provided that acute ketamine administration leads to dopamine release in the rodent brain and the implications for understanding psychiatric disorders, in particular substance abuse, schizophrenia, and the potential antidepressant properties of ketamine, and comparisons with stimulants and other NMDA antagonists. Expand
Schizophrenia-Like Dopamine Release Abnormalities in a Mouse Model of NMDA Receptor Hypofunction
TLDR
It is suggested that PV GABAergic neuron-NMDAR hypofunction in postnatal development confers bidirectional NAc hyper- and mPFC hypo-sensitivity to amphetamine-induced dopamine release, similar to that classically observed in schizophrenia pathophysiology. Expand
Glutamate Pharmacological Models Relevant to Schizophrenia and Psychosis: Can a Receptor Occupancy Normalization Approach Reduce the Gap between Animal and Human Experiments?
TLDR
Using a receptor occupancy approach, the hypothesis that consideration of pharmacokinetics and pharmacodynamics of NMDA-R antagonists in published studies may help to explain some of the differences between animal and human experiments is tested. Expand
Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial
TLDR
It is found that ketamine was devoid of adverse neurocognitive effects at 7 days post treatment and that slower baseline processing speed was associated with greater antidepressant response. Expand
Ketamine: Neurotoxicity and Neurobehavioral Disorders
Abstract Ketamine acts as an N-methyl- d -aspartate (NMDA) receptor antagonist that was originally synthesized for use as a dissociative anesthetic, and remains widely used for this clinicalExpand
A key role of the basal ganglia in pain and analgesia - insights gained through human functional imaging
TLDR
The basal ganglia are composed of several nuclei involved in neural processing related to the execution of motor, cognitive and emotional activities and are uniquely involved in thalamo-cortico-BG loops to integrate many aspects of pain. Expand
Chronic ketamine use and psychotic symptomatology
This thesis examines the effects of chronic use of ketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, on subjective experience and cognition. It is important to explore theExpand
Interaction between effects of genes coding for dopamine and glutamate transmission on striatal and parahippocampal function
TLDR
Functional magnetic resonance imaging provides evidence that interactions between the dopamine and the glutamate system, thought to be altered in psychosis, have an impact in executive processing which can be modulated by common genetic variation. Expand
Role of copper in depression. Relationship with ketamine treatment.
TLDR
It is necessary to carry out further studies related to copper and ketamine in depression treatment and observation of copper serum levels in patients treated with ketamine may provide important information about connections between NMDAR antagonistic agents and trace elements antagonistic to that receptor. Expand
Ketamine Usage at Subanesthetic Doses and Psychoactive Effects
Abstract Ketamine is a relatively safe dissociative anesthetic that works through antagonism at the N-methyl- d -aspartate receptor. At subanesthetic doses, it produces an array of transientExpand
...
1
2
3
...

References

SHOWING 1-10 OF 62 REFERENCES
NMDA antagonist effects on striatal dopamine release: Microdialysis studies in awake monkeys
TLDR
MRI‐directed in vivo microdialysis findings suggest that in the primate, ketamine and PCP are not effective dopamine releasers, as has been suggested by previous imaging studies. Expand
Ketamine does not decrease striatal dopamine D2 receptor binding in man
TLDR
This controlled study indicates that ketamine does not decrease striatal [11C]raclopride binding, andstriatal dopamine release is of minor importance in the psychosis-like effects of ketamine. Expand
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia
TLDR
The increase in amphetamine-induced dopamine release induced by ketamine was comparable in magnitude to the exaggerated response seen in patients with schizophrenia, consistent with the hypothesis that the alteration of dopamine release revealed by amphetamine challenge in schizophrenia results from a disruption of glutamatergic neuronal systems regulating dopaminergic cell activity. Expand
NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans
TLDR
These data fail to demonstrate an effect of ketamine on [11C]raclopride BP and are consistent with microdialysis studies in rodents and nonhuman primates which reported only small effects of acute NMDA receptor blockade on extracellular striatal DA concentration. Expand
Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach
TLDR
Ketamine‐induced changes in 11C‐raclopride‐specific binding were significantly correlated with induction of schizophrenia‐like symptoms and the implications of this brain imaging method for studies of schizophrenia and the mechanism of action of antipsychotic drugs are discussed. Expand
Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans.
TLDR
Evidence is provided that the glutamatergic NMDA receptor may contribute to psychotic symptom formation via modulation of the DA system through activation of dopaminergic systems. Expand
Ketamine anaesthesia has no effect on striatal dopamine metabolism in rats
TLDR
Results suggest that ketamine anaesthesia will not adversely affect studies investigating central DAergic mechanisms in rats, and even the dose regimen of ketamine produced no alteration in DA turnover for at least 9 h. Expand
Ketamine decreased striatal [11C]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: Multiparametric PET studies combined with microdialysis analysis
TLDR
The results suggest that the inhibition of glutamatergic neuronal activity modulates dopamine turnover in the striatum by simultaneous enhancement of the dynamics of dopamine synthesis and DAT availability to the same extent, resulting in no apparent changes in ECF dopamine concentration as measured by microdialysis. Expand
Glutamate Modulation of Dopamine Measured in Vivo with Positron Emission Tomography (PET) and 11C-Raclopride in Normal Human Subjects
TLDR
In vivo evidence is provided for the ability of ketamine to increase striatal dopamine concentrations, consistent with the role of the NMDA receptor in modulating dopamine function. Expand
Positron Emission Tomography Studies of Potential Mechanisms Underlying Phencyclidine-Induced Alterations in Striatal Dopamine
TLDR
Results suggest that PCP may be exerting some direct effects through the DAT and that GABA partially modulates NMDA-antagonist-induced increases in striatal DA. Expand
...
1
2
3
4
5
...